The Food and Drug Administration (FDA) is turning to AI to solve the problems with the lengthy approval process as the Trump administration invests in more automation amid layoffs for thousands of federal workers.
The administration hopes to use burgeoning technology to “furtherly increase efficiency.” American Medical Association Journal (Jama) An overview of agency priorities. The department's plans include using artificial intelligence to examine devices and drug applications. This is reportedly reduced several years from the approval process, and includes AI computational modeling to reduce animal experiments. The plan also proposes to require only one major patient study to promote approval, which is part of an overhaul of the “legacy” process.
This article cites the success of Covid-19 operating speed as a precedent for the decline in release timelines, but many experts are skeptical. “Rethinking our approach to AI and balancing safety and accuracy while fostering innovation is a key priority for the FDA… The FDA and our great health professionals need to unite to consider fresh new approaches to the evolving health topics facing America today,” the report reads. “The FDA takes conflicts of interest seriously.”
Masculine light speed
Openai launches new smart models. Meet o3-pro.
This article was written by Vinay Prasad, director of the FDA's Center for Biological Evaluation and Research (CBER)., Food and Drug Commissioner Martin A. McCurry. Prasad and McCurry will attack U.S. Department of Health and Human Services Director Robert F. Kennedy, Junior Kennedy, attacking the nation's scientists and doctors, labeled “industry sock puppets,” exempt the Centers for Disease Control and Prevention (CDC) power generation committee, and boost AI's advisory advisory.
In May, the FDA launched its first AI-assisted science review pilot, aimed at “reducing the amount of unproductive busy work.” For FDA scientists and subject experts, according to Makary. That same month, experts advised Kennedy's Make America Healthy Again Initiative report.
